A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CDA / cytidine deaminase

[Related PubMed/MEDLINE]
Total Number of Papers: 151
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CDA  (>> Co-occurring Abbreviation)
Long Form:   cytidine deaminase
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. AUC
2019 Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species. DHA, GEM, ROS
2019 Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. AML, BM, MM
2019 The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. 5-AC, MDS
2019 The mitoNEET ligand NL-1 mediates anti-leukemic activity in drug resistant B-cell acute lymphoblastic leukemia. ALL, BMSC
2018 CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. AML, PM
2018 CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells. CML, RT-qPCR
2018 Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. ---
2018 Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. SNPs
10  2018 Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIalpha as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin. dCMPD, DFS, Topo IIa
11  2017 Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity. BS, UFB
12  2017 Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. ---
13  2017 DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. BTC, dCK, hENT1, RFS
14  2017 DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315. A3G, ss
15  2017 Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Bcl-2, BCL10, BRCA1, CNVs, EGF, EPHX1, ETV1, LSM3, MAP3K1, MST1R, NFKB1, PMS2, RALY, RRM2, SLC28A3, SNPs, TTF-1
16  2017 Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. CES1, Cp, HFS
17  2017 Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. AEs, CRP, DNMT1, F-cells, RBCs, SCD, THU
18  2017 Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. PK
19  2016 A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. UFB
20  2016 Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition. 5-FC, AT-MSCs, CDA/UPRT, LLC
21  2016 Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. HCC
22  2016 High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. dCK, hENT1, LINE1, MDS
23  2016 Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. CI, PDA, TAMs
24  2016 Of the Nine Cytidine Deaminase-Like Genes in Arabidopsis, Eight Are Pseudogenes and Only One Is Required to Maintain Pyrimidine Homeostasis in Vivo. NSH1
25  2016 Pyrimidine Salvage Enzymes Are Essential for De Novo Biosynthesis of Deoxypyrimidine Nucleotides in Trypanosoma brucei. TK
26  2015 Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. CRC, DAC, dCK, DNMT1, GEM, SFRP1
27  2015 An enzymatic assay for high-throughput screening of cytidine-producing microbial strains. HPLC
28  2015 CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. 5cadC, 5fdC, 5hmdC, 5mdC
29  2015 Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. BTC, dCK, hCNT3, hENT1, RRM1, SNPs
30  2015 Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. ---
31  2015 Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. HR, OR, ORR, OS
32  2015 Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. AK-AML, AML, ara-U, NC, NK-AML
33  2015 FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. ---
34  2015 Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. GO, GR, HDAC
35  2015 Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome. PM
36  2015 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. ---
37  2015 Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA. BS
38  2015 RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. AML, dCK, DNR, ENT1, RI, RRM1
39  2015 Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. ---
40  2015 The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia. AML, CI, OR, SNPs
41  2015 Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. GEM, LB, MSNP, PTX
42  2014 Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. NSCLC, OS, TTP, XPD
43  2014 Clinical potential of elacytarabine in patients with acute myeloid leukemia. AML, hENT1
44  2014 Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. THU
45  2014 Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. PDA, TAMs
46  2014 Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift? ---
47  2014 Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. ---
48  2014 SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. DNMT
49  2014 The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. CI, NSCLC, RR
50  2013 Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population. PCR
51  2013 Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). 5-FU, AUC, DFUR
52  2013 Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. AML, DNMT1, HPLC, MDS, OS
53  2013 Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. dCK, dFdU
54  2013 Site directed mutagenesis as a tool to understand the catalytic mechanism of human cytidine deaminase. ---
55  2012 Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. AML, dCK, MALDI-TOF MS, SNPs, WBC
56  2012 Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. OS, TTP
57  2012 Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. AML
58  2012 Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. 5-FU, OR, RTOG
59  2012 Flight of a cytidine deaminase complex with an imperfect transition state analogue inhibitor: mass spectrometric evidence for the presence of a trapped water molecule. FT-ICR MS
60  2012 Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. dFdU, GST, NSCLC, PK, SLC
61  2012 Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. GWAS, PXR
62  2012 Genetic polymorphisms of XPD and CDA and lung cancer risk. PCR-RFLP, XPD
63  2012 Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population. DPYD, TPMT
64  2012 Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. C-C, ERCC1, GSTP1, HR, NSCLC, OS, PFS, PG, XPD10, XRCC1
65  2012 High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. e.g., liver
66  2012 High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. ---
67  2012 Identification of cda gene in bighead carp and its expression in response to microcystin-LR. MC-LR
68  2012 Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity. cN-II, dCK, hENT1
69  2012 Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine PET. dCK, NA
70  2012 Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. THU
71  2011 Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. AIO, ASCO, EGFR, SNPs
72  2011 Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications. 5'-DFCR, 5'-DFUR, 5-FU, CES, THU, TP
73  2011 Crystal structure determination and dynamic studies of Mycobacterium tuberculosis Cytidine deaminase in complex with products. MD, MtCDA
74  2011 Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). CTPS, dCK, ENT1 and ENT2, NT5, TS
75  2011 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. CL, CNT, dFdU, ENT, G/G, GEM
76  2011 Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. dCK, dNTPs, PET
77  2011 Rescue of the orphan enzyme isoguanine deaminase. cat
78  2011 Three-dimensional structure and catalytic mechanism of cytosine deaminase. ---
79  2011 [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. ---
80  2010 Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. ---
81  2010 Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. ALL, dCK, LL, MRD, SNPs
82  2010 Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. 5'-NT, dCK, ERCC1, hENT1, NSCLC
83  2010 Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. 5'-NT, dCK, RRM1
84  2010 High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. HRM
85  2010 Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo. CNDAC, dCyd
86  2010 PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population. ---
87  2010 Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. dFdU, NSCLC
88  2010 Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. dCK, dFdU
89  2010 Role of tyrosine 33 residue for the stabilization of the tetrameric structure of human cytidine deaminase. ---
90  2010 Structural and functional analyses of Mycobacterium tuberculosis Rv3315c-encoded metal-dependent homotetrameric cytidine deaminase. MtCDA
91  2010 Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. dCK
92  2010 [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]. dCK, ERCC1
93  2009 Contrasting behavior of conformationally locked carbocyclic nucleosides of adenosine and cytidine as substrates for deaminases. ADA
94  2009 Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. AML, CCG, IDA-DCTER, IDA-FLAG, TRM
95  2009 Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. ---
96  2009 Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines. CI, dCK, NSCLC
97  2009 Synthesis and conformational analysis of locked carbocyclic analogues of 1,3-diazepinone riboside, a high-affinity cytidine deaminase inhibitor. ---
98  2008 Characterization of reproduction-specific genes in a marine bivalve mollusc: influence of maturation stage and sex on mRNA expression. CnA, TSSK, Vg
99  2008 Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. ---
100  2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. ERCC1, NSCLC, OS, TTP, XPD